| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperlipidemias | D006949 | 73 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jenkins H et al. | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | 2017 | Clin Drug Investig | pmid:27928738 |
| Mishima E et al. | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 | Intern. Med. | pmid:28674358 |
| Sun W et al. | Synergistic drug combination effectively blocks Ebola virus infection. | 2017 | Antiviral Res. | pmid:27890675 |
| Shimoyama T et al. | Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. | 2017 | Intern. Med. | pmid:28674348 |
| Ustundag GH et al. | The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. | 2017 | Can J Gastroenterol Hepatol | pmid:28656129 |
| Peng X et al. | Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. | 2017 | Int J Med Sci | pmid:28638276 |
| Legendre T et al. | [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. | 2017 | Encephale | pmid:27178256 |
| Choi HS et al. | Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. | 2017 | Jpn. J. Infect. Dis. | pmid:27169951 |
| Pastukh N et al. | GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. | 2017 | Helicobacter | pmid:29058343 |
| Tognetti L et al. | Bullous impetigo during interstitial pneumonitis. | 2017 | G Ital Dermatol Venereol | pmid:29050448 |
| Antonakos N et al. | Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. | 2017 | Crit Care | pmid:28274246 |
| Koratala A et al. | Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. | 2017 | Blood Purif. | pmid:28268216 |
| Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
| Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
| Makihara K et al. | Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. | 2017 | Cancer Chemother. Pharmacol. | pmid:28711984 |
| Fohner AE et al. | PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. | 2017 | Pharmacogenet. Genomics | pmid:28146011 |
| Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
| Awan S et al. | Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. | 2017 | Lung Cancer | pmid:28213005 |
| Su J et al. | Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. | 2017 | Medicine (Baltimore) | pmid:28207505 |
| Branquinho D et al. | Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? | 2017 | BMC Gastroenterol | pmid:28202013 |